Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Xetra  >  Evotec AG    EVT   DE0005664809

EVOTEC AG

(EVT)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Evotec : to acquire Just Biotherapeutics, Inc.

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/20/2019 | 04:30pm EDT

DGAP-Ad-hoc: Evotec SE / Key word(s): Takeover
Evotec SE to acquire Just Biotherapeutics, Inc.

20-May-2019 / 22:24 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


Hamburg, Germany - Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809, WKN 566480) announced today the signing of a definitive agreement under which Evotec will acquire Just Biotherapeutics, Inc. ("Just.Bio") based in Seattle, WA, USA for up to US$ 90 m (approx. EUR 81 m; EUR/$ fx rate of 1.117) including potential performance-based earn-out components expected within the next three years. The acquisition of 100% of the issued and outstanding equity interests of the company will be paid in cash.

Just.Bio is a unique technology company that integrates highly synergistic scientific expertise and technologies for design, development, and manufacturing of biologics. The acquisition grows Evotec's business into a comprehensive offering including biologics in therapeutic areas such as oncology, CNS, pain, inflammation, metabolics, and infectious diseases. Just.Bio has approx. 90 employees, mainly scientists, all working at a state-of-the-art discovery, development and manufacturing facility in Seattle, WA, USA.

The completion of the transaction is subject to customary closing conditions. The acquisition is expected to close in the second quarter of 2019.

- End of ad hoc notification -

Contact: Dr Werner Lanthaler, Chief Executive Officer, Evotec SE, Manfred Eigen Campus, Essener Bogen 7, 22419 Hamburg, Germany, Phone: +49(0)40560 81-242, werner.lanthaler@evotec.com


20-May-2019 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: Evotec SE
Manfred Eigen Campus / Essener Bogen 7
22419 Hamburg
Germany
Phone: +49 (0)40 560 81-0
Fax: +49 (0)40 560 81-222
E-mail: info@evotec.com
Internet: www.evotec.com
ISIN: DE0005664809
WKN: 566480
Indices: MDAX, TecDAX
Listed: Regulated Market in Berlin, Frankfurt (Prime Standard); Regulated Unofficial Market in Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 813731

 
End of Announcement DGAP News Service

813731  20-May-2019 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=813731&application_name=news&site_id=zonebourse

© EQS 2019
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on EVOTEC AG
06/13EVOTEC : bags US$23.8m to fight tuberculosis
AQ
06/12EVOTEC : bags $23.8m to fight tuberculosis
AQ
06/11EVOTEC : receives $ 23.8 m grant to join the global fight against tuberculosis
AQ
06/10EVOTEC : Receives $ 23.8 m grant to join the global fight against tuberculosis
EQ
06/06EVOTEC : and Celgene further expand iPSC collaboration including new cell type
AQ
06/05EVOTEC : And celgene further expand ipsc collaboration including new cell type
EQ
05/31EVOTEC SE : Release according to Article 41 of the WpHG [the German Securities T..
EQ
05/31EVOTEC SE : Notification and public disclosure of transactions by persons
EQ
05/29EVOTEC SE : Notification and public disclosure of transactions by persons
EQ
05/21EVOTEC : jump-starts biologics with acquisition of Just Biotherapeutics
AQ
More news
Financials (€)
Sales 2019 414 M
EBIT 2019 73,4 M
Net income 2019 53,5 M
Finance 2019 6,17 M
Yield 2019 -
P/E ratio 2019 58,96
P/E ratio 2020 57,65
EV / Sales 2019 7,80x
EV / Sales 2020 6,78x
Capitalization 3 240 M
Chart EVOTEC AG
Duration : Period :
Evotec AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EVOTEC AG
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 7
Average target price 26,5 €
Spread / Average Target 22%
EPS Revisions
Managers
NameTitle
Werner Lanthaler Chief Executive Officer
Wolfgang Plischke Chairman-Supervisory Board
Craig L. Johnstone Chief Operating Officer & Member-Management Board
Enno Spillner Chief Financial Officer
Cord E. Dohrmann Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
EVOTEC AG31.59%3 664
IQVIA HOLDINGS INC21.63%26 223
LONZA GROUP29.21%24 012
CELLTRION, INC.--.--%20 953
INCYTE CORPORATION22.20%17 061
EXACT SCIENCES CORPORATION73.98%13 037